SRR35579834
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.410
- HEDGEHOG_SIGNALING+0.400
- MYOGENESIS+0.380
- TNFA_SIGNALING_VIA_NFKB+0.340
- ANGIOGENESIS+0.310
- APICAL_JUNCTION+0.310
- WNT_BETA_CATENIN_SIGNALING+0.310
- TGF_BETA_SIGNALING+0.290
- COAGULATION+0.250
Top 10 suppressed
- E2F_TARGETS-0.550
- OXIDATIVE_PHOSPHORYLATION-0.540
- MYC_TARGETS_V1-0.480
- G2M_CHECKPOINT-0.440
- MTORC1_SIGNALING-0.420
- MYC_TARGETS_V2-0.410
- DNA_REPAIR-0.390
- GLYCOLYSIS-0.350
- PROTEIN_SECRETION-0.290
- UNFOLDED_PROTEIN_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A2LN-01A-21R-A18M-07 | — | A | 0.946 |
| 2 | SRR8613726 | — | A | 0.916 |
| 3 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.914 |
| 4 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.912 |
| 5 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.910 |
| 6 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.908 |
| 7 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.905 |
| 8 | SRR8613732 | — | A | 0.904 |
| 9 | MBCProject_3896_T1_RNA | — | A | 0.903 |
| 10 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.900 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.540 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |